Identify Targets Like a Pro€¦ · The dysfunction of potassium channels has been associated with...
Transcript of Identify Targets Like a Pro€¦ · The dysfunction of potassium channels has been associated with...
Identify Targets Like a ProSolutions for identifying early leads against GPCRs and ion channel targets
Our FLIPR Tetra® High-Throughput Cellular Screening System is fast, reliable, and remarkably easy to configure. The system is optimized for use with both fluorescence and luminescence, and adapts readily to your assay format with user-changeable 96-, 384-, and 1536-well heads.
Comparison of intracellular calcium measurements ..... 2
Comparison of a novel calcium assay to fluorescence-based calcium flux assays ........................... 3
Calcium release-activated channel (CRAC) assays ....... 4
Potassium ion channel assay for high-throughput screening ..................................................................................... 5
Characterization of hERG channel blockers .................... 6
Homogeneous solution for GPCR assays ......................... 7
Live Cell Gi- and Gs- coupled GPCR second messenger signaling ................................................................ 8
Compound effects upon calcium transients in Cor.4U human iPSC cardiomyocytes ................................................ 9
High-throughput cardiotoxicity assays using stem cell-derived cardiomyocytes ............................................... 10
Optimization of NaV1.5 channel assay .................................. 11
Cryopreserved BacMam-transduced Aequorin cells .. 12
Optional FLIPR Tetra System assay configurations ....... 13
eBook contents
For more information, visitmoleculardevices.com/FLIPR
2moleculardevices.com/FLIPR
Calcium mobilization assay principle. Increase in cytosolic calcium can be detected by fluorescence measurement using calcium-sensitive indicator dyes.
Carbachol dose-response curves. Calcium mobilization by carbachol in CHO M1WT3 cells in three formats generated with the FLIPR Calcium Assay Kit on the FLIPR Tetra System. (A) 96-well; (B) 384-well; (C) 1536-well.
• Perform high-throughput, functional cell-based assays
• Quickly evaluate changes in intracellular calcium
• Homogeneous, fast and reliable fluorescence assay
Comparison of intracellular calcium measurementsG protein-coupled receptors (GPCRs) play an important role in cell signaling. When the receptor is activated by a ligand, receptor conformation is changed, triggering G-protein activation inside the cell. An active G protein has the potential to induce various cascades of intracellular messengers including calcium. The FLIPR Tetra System performs high-throughput, functional cell-based assays and is the system of choice in drug discovery for evaluating changes in intracellular calcium detected through use of fluorescent calcium-sensitive reporter dyes. Here we provide a basic protocol for performing a calcium mobilization assay on the FLIPR Tetra System using the FLIPR® Calcium Assay Kit, a homogeneous, fast and reliable fluorescence assay.
Download Application Note
Carbachol (nM)
Carbachol (nM)
Carbachol (nM)
RLU
RLU
RLU
A
B
C
3moleculardevices.com/FLIPR
• Enable low signal screens, including endogenous, primary or stem cell targets
• Lower background fluorescence significantly with masking technology
• Increase signal-to-noise ratio without removing growth media
Comparison of a novel calcium assay to fluorescence-based calcium flux assaysCell-based calcium flux assays are widely used in high-throughput screening (HTS) for identification of GPCR agonists and antagonists as well as other applications such as cardiac beating assays. Here we introduce a reagent system utilizing a novel calcium-sensitive ionophore that has a larger signal window with low background while maintaining Z' factors.
Download Poster
Comparison of Calcium 6 kits to other calcium flux assays. Each assay was incubated at optimal time for dye loading. Fluo-4 wash assay had the smallest signal window due to greater cell manipulation and extracellular fluorescence background. Both Calcium 6 and Calcium 6-QF kits provided the highest signal windows compared to the other kits or Fluo-4 Wash. EC50 values were preserved across all assays and Calcium 6 Kits showed Z at EC80 > 0.84 in the agonist assay and Z at IC80 > 0.76 in the antagonist assay.
Optimization of assay incubation time shows that both Calcium 6 and Calcium 6-QF assays benefited from a 2 hour incubation to achieve maximum signal window due to larger molecule size. Calcium 5 Kit and competitor dyes were incubated at their optimal incubation time of one hour. All assays were run with CHO-M1 cells in buffer. EC50 values were comparable to historical values (data not shown) and Z @ EC80 values were > 0.8.
60 Minute incubation
-5 -4 -3 -2 -1 0 10
1
2
3
4
5
6Ca5Ca6Ca6-QF
Log [carbachol] mM
DF/
F (m
ax-m
in)
120 Minute Incubation
-5 -4 -3 -2 -1 0 10
1
2
3
4
5
6Ca5Ca6Ca6-QF
Log [carbachol] mM
DF/
F (m
ax-m
in)
Signal window comparisonat optimal incubation time
-5 -4 -3 -2 -1 0 10
1
2
3
4
5
6 Ca5Ca6 120 minCa6-QF120 min
Log [carbachol] mM
DF/
F (m
ax-m
in)
C HO-M1 C ells in B uffer
-5 -4 -3 -2 -1 0 10
1
2
3
4
5Calcium 6
Calcium 6-QFCalcium 5
Competitor
2 µM Fluo-4W
4 µM Fluo-4W
Ca 6 Ca6-QF Ca 5 Competition 2 µM Fluo4 4 µM Fluo-4
EC50 (nM) 16 17 23 20 25 21
Z at EC80 0.88 0.84 0.89 0.85 0.86 0.71
Log [carbachol] mM
DF
/F (
ma
x-m
in)
C HO-M1 C ells in B uffer
-5 -4 -3 -2 -1 0 10
1
2
3
4
5Calcium 6
Calcium 6-QF
Calcium 5
Competitor
2 µM Fluo-4W
4 µM Flluo-4W
Ca 6 Ca6-QF Ca 5 Competition 2 µM Fluo-4 4 µM Fluo-4
IC50 (nM) 6 4 3 5 3 3
Z at IC 80 0.77 0.76 0.7 0.83 0.53 0.1
Log [Atropine] mM
DF
/F (
ma
x-m
in)
60 Minute incubation 120 Minute incubation Signal window comparison at optimal incubation time
Log [Carbachol] mM Log [Carbachol] mM Log [Carbachol] mM
DF
/F (m
ax-m
in)
DF
/F (m
ax-m
in)
DF
/F (m
ax-m
in)
DF
/F (m
ax-m
in)
DF
/F (m
ax-m
in)
Log [Carbachol] mM Log [Atropine] mM
4moleculardevices.com/FLIPR
• Background fluorescence is reduced by masking technology
• Dye formulation delivers larger signal window due to enhanced retention of dye within the cell
• Calcium 6-QF formulation is a flexible option for quench-sensitive targets or multiplexing applications
Calcium release-activated channel (CRAC) assaysCalcium release-activated calcium (CRAC) channels play an important role in intracellular Ca2+ homeostasis. Like other store-operated calcium (SOC) channels, currents through the CRAC channel (ICRAC) are activated by depletion of calcium in the endoplasmic reticulum (ER) and serve the purpose of slowly replenishing the ER with Ca2+. CRAC channels are considered key for the activation of immune cells. Abnormalities in ICRAC have been associated with certain primary immunodeficiencies, acute pancreatitis and abnormal cell proliferation. Hence the development of a reliable and sensitive CRAC channel assay may lead to the detection of novel therapeutic agents aimed at treating these human disorders.
Here we compare ratiometric Fura-2 AM, non-ratiometric Fluo-4 NW and the FLIPR® Calcium 6 and Calcium 6-QF Assay Kits in two CRAC channel assays, using both RBL and Jurkat cells.
Download Poster
CRAC channel inhibitor assay in adherent RBL-2H3 cells. Dyes were loaded according to protocols outlined in the methods section and inhibition curves obtained with YM 58483 (l), Econazole (l) and 2-APB (l). The rank order of inhibitor potency in this assay was YM 58483 » 2-APB > Econazole.
CRAC channel inhibitor assay in suspension Jurkat cells. Dyes were loaded according to protocols outlined in the methods section and inhibition curves obtained with YM 58483 (l), Econazole (l) and 2-APB (l). The rank order of inhibitor potency in this assay was YM 58483 » Econazole ≥ 2-APB.
RBL-2H3 (Calcium 6) RBL-2H3 (Fluo-4 NW) RBL-2H3 (Calcium 6QF) RBL-2H3 (Fura-2 AM)
[Ligand] (log M) [Ligand] (log M) [Ligand] (log M) [Ligand] (log M)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Jurkat (Calcium 6)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Jurkat (Fluo-4 NW)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Jurkat (Calcium 6QF)
Re
spo
nse
(sig
nal/b
ackg
roun
d)
Re
spo
nse
(340
/38
0 r
atio
)
Jurkat (Fura-2 AM)
5moleculardevices.com/FLIPR
• Functional measurement of K+ channel activities
• Homogeneous no-wash protocol enhances ease-of-use and reduces total assay time
• Reduced well-to-well variation and improved data quality compared to non-homogeneous formats
Potassium ion channel assay for high-throughput screeningPotassium channels are responsible for a variety of cellular functions including the maintenance and regulation of membrane potential, secretion of salts, hormones, and neurotransmitters. The dysfunction of potassium channels has been associated with many human diseases. Off-target drug effects on potassium channels have been linked to cardiac toxicity. Due to their crucial physiological functions and their implication in drug-induced toxicity, potassium channels are heavily investigated by the pharmaceutical industry. Furthermore, cell-based functional assays have increasingly been used because they yield more physiologically-relevant results. Challenges exist in measuring K+ ion channel activity in a high-throughput format. A widely adopted technique is to use the fluorometric method where the binding of thallium to thallium-sensitive fluorescent dyes is utilized as a surrogate measurement of potassium channel activity.
Here we demonstrate how the FLIPR® Potassium Assay Kit analyzes potassium ion channel activities on the FLIPR Tetra System.
Download Poster
KV1.3 Channel Activity: Assay optimization with Tl+/K+ Titration. KV1.3 channel activity was measured with different K+ and Tl+ concentrations for optimal assay performance. [K+] = 10 mM (—), 20 mM (—), or 30 mM (—) was used as stimulus in the presence of 1 mM Tl+ (A), 2 mM Tl+ (B) and 3 mM Tl+ (C). Data were normalized to non-stimulated condition at 0 mM K+ (—).
hERG channel pharmacology. IC50 determination of hERG channel blockers using the FLIPR Potassium Assay Kit versus a non-homogeneous potassium assay kit. Cell media was removed to prevent potential serum interference of the IC50 determination. Cells were dye loaded for 1 hour at RT. The dye solution was replaced with assay buffer for the non-homogeneous assay. Compounds were then incubated with cells for 25 min at RT after dye loading. The assay was carried out using 1 mM Tl+ and 10 mM K+ as stimulus.
K v1.3 [ T i+ ] = 1 mM
0 50 100 150
1.0
1.5
2.0
2.5
3.0
Time (S econds )
Res
pons
e:B
asel
ine
(max
- m
in) Kv1.3 [ Tl+ ] = 2 mM
0 50 100 150
1.0
1.5
2.0
2.5
3.0
Time (Seconds)
Resp
onse
:Bas
elin
e (m
ax -
min
)
Kv1.3 [ Tl+ ] = 3 mM
0 50 100 150
1.0
1.5
2.0
2.5
3.0
Time (Seconds)
Resp
onse
:Bas
elin
e (m
ax -
min
)
Tl+ = 1 mM Tl+ = 2 mM Tl+ = 3 mMA B C
Time (Seconds) Time (Seconds) Time (Seconds)
Re
spo
nse
bas
elin
e (m
ax -
min
)
Re
spo
nse
bas
elin
e (m
ax -
min
)
Re
spo
nse
bas
elin
e (m
ax -
min
)
Log [Compound] M Log [Compound] M
Sig
nal o
ver
bac
kgro
und
(max
-min
)
Sig
nal o
ver
bac
kgro
und
(max
-min
)
Astemizole
Pimozide
Terfenadine
Astemizole
Pimozide
Terfenadine
6moleculardevices.com/FLIPR
• Functional measurement of K+ channel activity in a cell-based assay
• Homogenous no-wash protocol reduces well-to-well variation and simplifies the workflow
• Expanded signal window compared to non-homogenous assay
Characterization of hERG channel blockers using the FLIPR Potassium Assay KitDrug-induced inhibition of the human ether-à-go-go-related gene (hERG) ion channel has been related to the susceptibility of patients to potentially fatal ventricular tachyarrhythmia, torsade de pointes. In recent years, a number of FDA-approved drugs were withdrawn from the market due to their off-target effect on hERG. As a result, there has been an increasing need for identifying compounds that block the hERG channel at earlier stages in the drug discovery process. Here we present the utility of the FLIPR Potassium Assay Kit on the FLIPR Tetra System to investigate hERG compound activity.
Download Application Note
Optimization of hERG channel stimulant. Cells were incubated with dye and the stimulant buffers were added during detection on the FLIPR Tetra System. The concentration-dependent response of signal was characterized under different conditions. Optimal signal was obtained from the combination of 1 mM Tl+ and 10 mM K+ (final concentration) stimulant buffer diluted in chloride-free buffer.
Comparison of FLIPR Potassium Assay Kit results to a competitor kit. Concentration-dependent inhibition of hERG channel by reference compounds.
hE R G [ T l+ ] = 0.5 mM
0 40 80 120 160
1.0
1.5
2.0
2.5Control10 mM K+
20 mM K+
Time
Res
pon
se: b
asel
ine
hE R G [ T l + ] = 1 mM
0 40 80 120 160
1.0
1.5
2.0
2.5
Time
Res
pon
se: b
asel
ine
hE R G [ T l+ ] = 2 mM
0 40 80 120 160
1.0
1.5
2.0
2.5
Time
Res
pon
se: b
asel
ine
-10 -8 -6 -4 -20
1
2
3 CisaprideDofetilideTerfenadineHaloperidolPimozideFlunarizineAstemizole
L og [Inhibitor] M
Res
pons
e: b
asel
ine
(max
- m
in)
-10 -9 -8 -7 -6 -5 -40.0
0.5
1.0
1.5
2.0
2.5Astemizole-FLIPR K+
Pimozide-FLIPR K+
Terfenadine-FLIPR K+
Astermizole-FluxORPimozide-FluxORTerfenadine-FluxOR
L og [Inhibitor] M
Res
pons
e: b
asel
ine
(max
- m
in)
Tl+ = 0.5 mM
Time
Re
spo
nse
bas
elin
e
Re
spo
nse
bas
elin
e
Re
spo
nse
bas
elin
e
Time Time
Tl+ = 1 mM Tl+ = 2 mM
Log [Inhibitor] MLog [Inhibitor] M
Re
spo
nse
: bas
elin
e (m
ax -
min
)
Re
spo
nse
: bas
elin
e (m
ax -
min
)
7moleculardevices.com/FLIPR
• Superior signal-to-noise ratio over competitive dyes and kits
• Robust data, with Z' factor > 0.9
• Low well-to-well variation, even with frozen cells
• True homogeneous protocol, mix-and-read
Homogeneous solution for GPCR assaysCell-based assays have become an indispensable method for screening and compound profiling in the early drug discovery process. To date, such assays have proven to be some of the most reliable and reproducible methods in receptor characterization studies, primary screening campaigns and compound profiling programs. For Gq-coupled GPCR targets specifically, homogeneous fluorescent calcium flux assays with masking technology are the methodology of choice.
Combining a novel fluorophore and proven masking technology, the FLIPR Calcium 5 Assay Kit delivers reliable pharmacology, a larger signal window, and improved assay performance. With the FLIPR Calcium 5 Assay Kit and the FLIPR Tetra System, consistent screening of a variety of receptors and targets, especially those with small calcium signal responses, can be obtained in an easy-to-use, homogeneous format.
Download Application Note
Kinetic traces from the FLIPR Tetra System. Representative signal traces on the FLIPR Tetra System for acetylcholine induced agonism of the endogenous muscarinic M3-receptor in “assay ready” 1321N1 cells compared using different calcium assay kits.
Antagonism: comparison of calcium assay signal window. Atropine inhibition of calcium flux in response to an EC80 challenge of acetylcholine in “assay ready” 1321N1 cells, evaluated with six different calcium reagents on the FLIPR Tetra System.
Agonism: comparison of calcium assay signal window. Comparison of the fluorescent signal in “assay ready” 1321N1 cells during acetylcholine stimulation of the endogenous muscarinic M3-receptor. This illustrates the enhanced signal-to-background ratio obtained by the FLIPR Calcium 5 Assay Kit with proven masking technology.
Time (seconds)
0 20
FLIPR Calcium 5 Assay KitFluo-4 AM Calcium IndicatorFluo-4 NW Calcium Assay KitrFluo-4 Direct Calcium Assay KitFluoForte Calcium Assay KitScreen Quest Rhod-4 NW Calcium Assay Kit
40 60 80 100 120
% o
f bas
elin
e
100
150
200
250
300
350
10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
100
150
200
250
300
350
Fluo-4 Direct
Calcium 5
FluoForte
Fluo-4 NW
Rhod-4 NW
Fluo-4 AM
[Acetylcholine] (M)
Re
spo
nse
(% b
ase
line
)
10 -12 10 -10 10 -8 10 -6 10 -4
100
150
200
250
300
Fluo-4 Direct
Calcium 5
FluoForte
Fluo-4 NW
Rhod-4 NW
Fluo-4 AM
[Atropine] (M)
Re
spo
nse
(% b
ase
line
)
Time (seconds)
% o
f bas
elin
e
Acetylcholine (M)
Re
spo
nse
(% b
ase
line
)
Re
spo
nse
(% b
ase
line
)
Atropine (M)
8moleculardevices.com/FLIPR
• GloSensor cAMP Assay is demonstrated on the FLIPR Tetra System as a live cell HTS screening application for Gi- and Gs-coupled GPCRs
• Use of the FLIPR Tetra System with GloSensor cAMP Assay enables kinetic measurement of Gi- and Gs-coupled receptor signaling not possible using endpoint assays on standard plate readers
Live cell Gi- and Gs-coupled GPCR second messenger signalingDetection of Gi- and Gs-coupled GPCR second messenger signal activity has been traditionally accomplished using assays such as radioactive binding or endpoint cAMP assays that require cell lysis. Such assays measure activity at a single time point in the cellular response and do not provide kinetic information. Another option utilizes forced-coupling of Gi- and Gs-GPCRs to Gα16 followed by fluorescence detection of calcium flux upon agonist receptor activation. Again, this assay is sub-optimal as it does not signal through the biorelevant cAMP pathway.
Here we demonstrate endogenous receptor activity in CHO-K1 and HEK-293 cell
lines stably expressing the GloSensor™ plasmid using the FLIPR Tetra System.
Download Application Note
Gi-coupled agonsim. Gi-coupled GPCR receptor agonism results in a
reduction in signal correlated with reduction in cAMP inside the cell. Baseline increase in cAMP activity was induced by the addition of forskolin. Using stable P2Y receptor in CHO-K1 cells, we compared results upon addition of forskolin either before or after the agonist. 10 µM forskolin addition followed 15 minutes later by addition of agonist Peptide YY(3-36) on the FLIPR Tetra System.
HEK-293 cells over expressing Gi-coupled D4 receptor. HEK-293 cells over expressing Gi-coupled dopamine D4 receptor from Multispan, Inc. were
transiently transfectd with GloSensor cAMP-22F plasmid. Ligand was added on-line to the wells, followed by 5 minute incubation. Continuing the assay, FLIPR Tetra System added 10 µM forskolin to stimulate cAMP production in the cell. Inhibition of forskolin mediated cAMP production by Dopamine.
Gs-coupled GPCR agonist and antagonist. Transient transfection of GloSensor cAMP-22F and endogenous Gs-coupled cAMP response in HEK 293 cells. (A) Response to isoproterenol and (B) inhibition of the response to 100 nM isoproterenol by propranolol. Results are comparable to those
obtained from the experiment performed with the stable GloSensor HEK-22F cell line.
25000
20000
15000
10000
5000
0
RLU
(max
-min
)
-12 -11 -10 -9 -8 -7 -6Log [Dopamine] MLog [Peptide YY(3-36)] µM
2000
1500
1000
500
0
RLU
(min
imum
)
-4 -2 0 2
RLU
(max
-min
)
40000
30000
20000
10000
0-11 -10 -9 -8 -7 -6 -5
Log [Isoproterenol] M
RLU
(max
-min
)
30000
20000
10000
0-12 -11 -10 -9 -8 -7 -6 -5
Log [Propranolol] M
A B
IC50 = .014 µM
Z at IC50 = 0.5
IC50 = 0.66 nM
Z at IC50 = 0.67
EC50 = 24 nM
Z at EC80 = 0.62 IC50 = 0.86 nM
Z at IC50 = 0.87100 nM Isoproterenol
9moleculardevices.com/FLIPR
• Evaluate compound toxicity and efficacy earlier in the drug discovery process
• Analyze cardiotoxicity profiles in a biorelevant system
• Scale assay size to meet throughput requirements
Compound effects upon calcium transients in Cor.4U human iPSC cardiomyocytesThere is a growing need for highly predictive in vitro cardiotoxicity assays that use biologically relevant cell-based models and are suitable for high-throughput screening. iPS cell-derived cardiomyocytes are especially attractive cell models because they represent gene expression profiles as well as phenotypic characteristics similar to native cardiac cells.
The calcium sensitive dye in the EarlyTox™ Cardiotoxicity Kit makes it possible to evaluate concentration-dependent modulation of calcium peak frequency and illustrate oscillation patterns in Axiogenesis Cor.4U® iPS cell-derived
cardiomyocytes using the FLIPR Tetra System.
Download Application Note
Calcium signal oscillation. In the experimental control, calcium signal oscillation reflects changes in cytoplasmic calcium concentration in Cor.4U iPS cell-derived cardiomyocytes measured with the EarlyTox Cardiotoxicity Kit on the FLIPR Tetra System.
Isoproterenol β adrenergic agonist. Left: Calcium signal oscillation in response to 0.37 µM isoproterenol. Right: Three minutes post compound addition, increase in isoproterenol concentration increases beat frequency of iPS cell-derived cardiomyocytes from approximately 36 to 50 BPM.
Propranolol, a β adrenergic antagonist slows beat frequency in iPS cell-derived cardiomyocytes. Left: Beat pattern in response to 3.3 µM propranolol. Right: BPM at 3 minutes post compound addition slows from approximately 31 to 17 with increase in compound concentration.
0 10 20 302000
3000
4000
5000
6000
S econds
RFU
0 10 20 302000
3000
4000
5000
6000
S econds
RFU
0 10 20 30
2000
3000
4000
5000
6000
S econds
RFU
-3 -2 -1 0 130
40
50
60
L og [Is oproterenol] mM
BP
M
-2 -1 0 1 210
20
30
40
L og [P ropranolol] mM
BP
M
Seconds Log [Isoproterenol] mM
RF
U
BP
M
Seconds
RF
U
RF
U
Seconds Log [Isoproterenol] mM
BP
M
10moleculardevices.com/FLIPR
• Earlier prediction of compound toxicity and efficacy
• Robust, high throughput, biologically relevant assays
• Fast, simplified data analysis for compound prioritization
High throughput cardiotoxicity assays using stem cell-derived cardiomyocytesThe development of highly predictive in vitro assays suitable for high throughput screening is critical to improve the inefficiencies and high costs associated with cardiac safety compound failure. Traditional methods for characterizing cardiotoxic compounds are labor-intensive and slow.
With ScreenWorks® Peak Pro Software running on the FLIPR Tetra System, you can quickly and easily characterize cardiotoxic compounds using stem cell-derived cardiomyocytes. Human cardiomyocytes derived from stem cell sources can greatly accelerate the development of new chemical entities and improve drug safety by offering more biologically relevant cell-based models than those
presently available.
Download Application Note
Cardiomyocyte assay capabilities. Cardiomyocyte contraction parameters calculated by ScreenWorks Peak Pro Software for two different wells.
Effects of β-adrenergic receptor agonists/antagonists and ion channel blockers. Dose response of six different compounds as measured by the FLIPR Tetra System in Calcium 5 loaded iPSC derived cardiomyocytes. Left: Change in frequency of contractions with dose. Right: Change in average peak width with dose.
All
A
C
D
E
F
G
H
I
J
K
M
N
0
P
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 241
Isoproterenol 10 mM 10 mM 10 mM 10 mM
Cisapride100 mM
Nifedipine1 mM
TTX Epinephrine 1 mM
Propranolol ACh
B
β-Adrenergic β-Adrenergic β-AdrenergicAgonist
hERGBlocker
L-type Ca Channel Blocker
Na Channel Blocker Agonist Blocker
Cholinergic Agonist
L
Conc
entr
atio
n
Cisapride
Time (Seconds)0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
Rel
ativ
e Li
ght U
nits
200
250
300
350
400
450
500
CONTROL
Time (Seconds)0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
Rel
ativ
e Li
ght U
nits
200
250
300
350
400
450
500
Parameter Buffer control
14 nM cisapride
Peak count 21 4
Frequency (min.) 13 2.2
Rise time (sec.) 0.51 1.04
Decay time (sec.) 8 14.2
Average peak width @ 10% amplitude (sec.)
1.9 16.6
1e-4 0.001 0.01 0.1 1 10 100 1000 1e4
0
10
20
30
40
50
60
1e-4 0.001 0.01 0.1 1 10 100 1000 1e4
0
10
20
30
40
50
60
1e-4 0.001 0.01 0.1 1 10 100 10000123456789
1011
1e-4 0.001 0.01 0.1 1 10 100 10000123456789
1011
Concentration (µM) Concentration (µM)
Beat
s pe
r m
inut
e
10%
pea
k w
idth
(se
c.)
Cisapride – hERG channel blocker – hERG channel blocker
Propranolol – Lidocaine – Na+ channel blockerIsoproterenol –
Epinephrine – ß-AR agonist ß-AR agonist
ß-AR agonistAstemizole
Be
ats
pe
r m
inut
e
10%
pe
ak w
idth
(se
c.)
Concentration (µM) Concentration (µM)
11moleculardevices.com/FLIPR
• Maximize cell line/channel/compound applicability with proprietary indicator dye
• Eliminate causes of data variability
• Detect bidirectional gradient changes to both variable and control conditions within a single experiment
Optimization of NaV1.5 channel assayVoltage-gated ion channels are present in the excitable cell membranes of heart, skeletal muscle, brain and nerve cells. Blocking or modulating such channels can have a therapeutic effect, or may interfere with normal cell function. As a result, compounds that affect voltage-gated ion channels are important targets in drug discovery. Cardiac Nav1.5 channels are classified as “Tetrodotoxin (TTX)-resistant.” The pharmacological significance of the Nav1.5 channel is that they are targets for the action of antiarrhythmic drugs and are also blocked by local anesthetics such as lidocaine.
FLIPR® Membrane Potential Assay Kits provide a rapid and reliable fluorescence-based method to detect changes in membrane potential brought about by compounds that modulate or block voltage-gated ion channels held open by veratridine. We offer two different no-wash formulations of FLIPR Membrane Potential Assay Kits: Blue and Red. Each kit uses a proprietary indicator dye, combined with different quencher to maximize cell line/ channel/compound applicability while eliminating causes of variability in the data.
Download Application Note
Modulation of NaV1.5 Channel in CHL Cells by Tetrodotoxin. Comparison of tetrodotoxin IC50 curves. (A) FLIPR Membrane Potential Red Assay Kit. (B) FLIPR Membrane Potential Blue Assay Kit. A larger response with a better Z’ factor is seen in FLIPR Membrane Potential Red Assay Kit.
Modulation of NaV1.5 Channel in CHL Cells by Lidocaine. Comparison of lidocaine IC50 curves. The FLIPR Membrane Potential Red Assay Kit (A) results in a greater fluorescence change and a more sensitive response to lidocaine compared to the FLIPR Membrane Potential Blue Assay Kit (B).
1250
1000
750
500
250
[tetrodotoxin] (µM)
RFU
(max
-min
)
0
1250
1000
750
500
250
0
10-2 10-1 100 101 102
FLIPR Membrane Potential Red Kit
IC50 = 0.79 µMZ at IC80 = 0.65n=8
[tetrodotoxin] (µM)
RFU
(max
-min
)
10-2 10-1 100 101 102
FLIPR Membrane Potential Blue Kit
IC50 = 2 µMZ at IC80 = 0.27n=8
1250
1000
750
500
250
[lidocaine] (µM)
RFU
(max
-min
)
0
1250
1000
750
500
250
0
10-1 100 101 102 103 104 10-1 100 101 102 103 104
FLIPR Membrane Potential Red Kit
IC50 = 9.55 µMZ at IC80 = 0.49n=8
[lidocaine] (µM)
RFU
(max
-min
)
FLIPR Membrane Potential Blue Kit
IC50 = 51.31 µMZ at IC80 = 0.46n=8
IC50 = 0.79 µMZ at IC80 = 0.65n = 8
Tetrodotoxin (µM)
RF
U(m
ax-m
in)
Tetrodotoxin (µM)
RF
U(m
ax-m
in)
IC50 = 2 µMZ at IC80 = 0.27n = 8
A B
A B
RF
U(m
ax-m
in)
RF
U(m
ax-m
in)
Lidocaine (µM) Lidocaine (µM)
IC50 = 9.55 µMZ at IC80 = 0.49n = 8
IC50 = 51.31 µMZ at IC80 = 0.46n = 8
12moleculardevices.com/FLIPR
• These cell lines can be used to produce robust assay results in both 384-well and 1536-well formats on the FLIPR Tetra System with Aequorin options
• Aequorin-based suspension assays with frozen cells demonstrate both instrument and cell performance during extended assays without significant shift in EC50 or Z’ factor
• The EC50 values remain within one half log of expected results and there is little reduction in signal intensity over time
Cryopreserved BacMam-transduced Aequorin cellsAequorin is a photo-sensitive protein that emits luminescent light in response to calcium. Cryopreserved cells as reagents in Aequorin-based calcium flux assays decouples the tissue culture process from high-throughput screening while improving overall assay performance. The need for culturing cells in plates is eliminated.
Here we demonstrate the performance of cryopreserved BacMam-transduced Aequorin cells (provided by GSK) in 384- well and 1536-well formats. Combined with the FLIPR Tetra System equipped with Aequorin options, cryopreserved cells
are a powerful tool in the identification of lead compounds in drug discovery.
Download Poster
Cell Titration and CRC Assay measured with FLIPR Tetra System. In a 384-well plate, frozen Bacmam Transduced Aequorin Cells were titrated
against a CRC of target agonist. In this assay, cells were pre-plated in suspension prior to addition of compound.
Z’ factor over time during BacMam Aequorin Suspension Cell Assays. Recording of whole plate Z’ factor during extended plate screening assays. 384-well plates contained 22 columns of EC80 reference compound and 2 columns of negative controls. Average Z’ factor = 0.7.
Change in signal over time during BacMam Aequorin Suspension Cell Assays. Change in RLU over time during six hour 384-well suspension cell experiment. Cells were added at 2,500/well.
RLU
(max
-min
)
[Agonist] nM
Z’ F
acto
r
Time (min)
Time (min)
RLU
(AU
C)
Expected EC50 = 175 nM
Viability > 95%
Average Z' = 0.7
The trademarks used herein are the property of Molecular Devices, LLC or their respective owners. Specifications subject to change without notice. Patents: www.moleculardevices.com/productpatents FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
Contact Us
Phone: +1-800-635-5577Web: moleculardevices.comEmail: [email protected] our website for a current listing of worldwide distributors.
©2016 Molecular Devices, LLC 3/16 V2 Printed in USA
Optional FLIPR Tetra System assay configurationsWe offer a broad range of user-installable optics for the FLIPR Tetra System to enable the application flexibility you require to support your research and screening. You can easily change the LEDs and filters on the system in just a few minutes.
Download collateral
• Brochure
• Data Sheet
Target assay application Ex LED (nm) Em filter (nm)
Fluorescence
Fura-2 335-345 and 380-390 475-535
MQAE 360-380 400-460
Voltage Sensor Probe (VSP) 390-420 440-480
Tango GPCR assay system (FRET) 390-420 440-480, 515-575
CFP; eCFP/YFP 420-455 475-535
FLIPR Calcium Assay 470-495 515-575
Calcium (Fluo-4), Calcium (Fluo-8) 470-495 515-575
Calcium (Fluo-3) 495-505 526-586
JC-1 495-505 565-625
FLIPR Membrane Potential Assay 510-545 565-625
Rhodamine-2, Rhodamine-4 510-545 565-625
Alexa 633 and Bodipy 610-626 646-706
Luminescence
Aequorin Luminescence
GloSensor Luminescence
BRET 2 Luminescence 440-480, 526-586
Additional dyes and applications may be addressed. Ask us for more information about your applications of interest. Custom filter holders are available to work with additional emission filters for your applications.
Ordering information
Product Description Part number
FLIPR Tetra System High-Throughput Cellular Screening System FLIPR
FLIPR Tetra Pipette Tips Black, non-sterile, 96-well 50 racks/case 9000-0762
FLIPR Tetra Pipette Tips Clear, non-sterile, 96-well 50 racks/case 9000-0761
FLIPR Tetra Pipette Tips Black, non-sterile, 384-well 50 racks/case 9000-0764
FLIPR Tetra Pipette Tips Clear, non-sterile, 384-well 50 racks/case 9000-0763
View related webinars
• Innovative assays for the FLIPR Tetra System
• Developing an in vitro Tl+ flux assay for potassium channel agonist identification
• Novel in vitro assay tools for cardiac toxicity and discovery
• Optogenetics and the FLIPR: how to use light to set up a Cav1.3 high-throughput screening assay